Skip to main content
Medical information Clinical review pending

Genetic Testing

OncoPro Liquid Biopsy Test

The OncoPro Liquid Biopsy Test is an advanced, non-invasive blood test using next-generation sequencing to analyze 73 cancer-related genes. It aids in cancer detection and monitoring.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (specific volume and tube type to be confirmed with the laboratory before booking).
Results
Approximately 35 working days. Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. Generally, no special preparation is required, but fasting may be requested.
Test priceKSh 386,100

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the OncoPro Liquid Biopsy Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients with symptoms suggestive of cancer.
  • ✓Individuals with a family history of cancer.
  • ✓Patients undergoing cancer treatment requiring monitoring.
  • ✓Monitoring for treatment response or disease progression.
  • ✓Identifying potential targeted therapy options.
02

In plain language

What this test helps you understand

Detects and monitors cancer by analyzing circulating tumor DNA (ctDNA) in a blood sample. Identifies specific genetic mutations in 73 cancer-related genes to inform diagnosis, prognosis, and treatment decisions.
The OncoPro Liquid Biopsy Test is an advanced diagnostic tool designed to detect and monitor cancer through a simple blood sample. This test utilizes next-generation sequencing (NGS) to analyze a 73 gene panel, providing crucial insights into the genetic makeup of tumors. Unlike traditional biopsy methods, the liquid biopsy is non-invasive, making it a preferred choice for patients and oncologists alike.

The OncoPro Liquid Biopsy Test measures specific genetic alterations associated with various types of cancer. The 73 gene panel includes critical genes such as EGFR, KRAS, BRCA1, and TP53, among others. By identifying these mutations, the test helps in understanding tumor behavior and guiding treatment decisions.

Results from the OncoPro Liquid Biopsy Test will be available within 35 working days. The report will detail the detected genetic alterations and their implications for treatment. It is essential to discuss these results with your oncologist to understand the next steps in your care plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. Generally, no special preparation is required, but fasting may be requested.
SampleBlood sample (specific volume and tube type to be confirmed with the laboratory before booking).
MethodologyNext-Generation Sequencing (NGS) analysis of circulating tumor DNA (ctDNA) from a blood sample, targeting a 73-gene panel.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects mutations present in the circulating tumor DNA. It may not detect all types of cancer or all mutations within a tumor. A negative result does not rule out cancer. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

A liquid biopsy is a test performed on a sample of blood to look for cancer cells or pieces of DNA from tumors that are circulating in the blood.
No, the test involves a simple blood draw, which is minimally invasive and generally painless.
Results are typically available within 35 working days, but confirm the current turnaround time with the laboratory before booking.
The panel includes genes commonly associated with various cancers, such as EGFR, KRAS, BRCA1, and TP53. The full list is available upon request.
Your oncologist or treating physician will interpret the results in the context of your medical history and discuss the implications with you.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp